Top

European Journal of Nutrition

Published in:

01-08-2019 | Original Contribution

Increased bioavailability of curcumin using a novel dispersion technology system (LipiSperse®)

Authors: D. Briskey, A. Sax, A. R. Mallard, A. Rao

Published in: European Journal of Nutrition | Issue 5/2019

Abstract

Purpose

Curcumin has been shown to deliver protective effects against numerous degenerative conditions associated with high levels of inflammation and oxidative stress. Owing to its poor bioavailability when delivered orally, it is difficult to deliver a high concentration therapeutic dose. LipiSperse^® is a novel delivery system that uses dispersion technology to enhance bioavailability of hydrophobic agents. In this study, we investigated the pharmacokinetics of a commercially available curcumin extract, with or without the curcumin-LipiSperse^® delivery complex.

Methods

Eighteen healthy male and female volunteers participated in this single equivalent dose, randomised, double-blinded study. Seven of those volunteers further participated in the crossover phase of the trial. Plasma concentrations were determined at baseline and at regular intervals over a 24-h period following 750 mg of curcuminoid ingestion.

Results

In both the parallel and crossover trial, Curcumin with LipiSperse^® delivered significantly higher plasma curcuminoid concentrations compared to the raw curcumin product (807 vs 318 ng/mL in the crossover trial).

Conclusions

The novel delivery system LipiSperse^® is safe in humans, and demonstrates superior bioavailability for the supply of curcumin when compared to a standard curcumin extract.

Prasad S, Aggarwal BB (2011) Turmeric, the golden spice: from traditional medicine to modern medicine. In: Benzie IFF, Wachtel-Galor S (eds) Herbal medicine: biomolecular and clinical aspects. 2nd edn., CRC Press, Boca Raton

Anand P, Kunnumakkara AB, Newman RA, Aggarwal BB (2007) Bioavailability of curcumin: problems and promises. Mol Pharm 4(6):807–818. https://doi.org/10.1021/mp700113r CrossRefPubMed

Ferrari E, Benassi R, Sacchi S, Pignedoli F, Asti M, Saladini M (2014) Curcumin derivatives as metal-chelating agents with potential multifunctional activity for pharmaceutical applications. J Inorg Biochem 139:38–48. https://doi.org/10.1016/j.jinorgbio.2014.06.002 CrossRefPubMed

Gupta SC, Prasad S, Kim JH, Patchva S, Webb LJ, Priyadarsini IK, Aggarwal BB (2011) Multitargeting by curcumin as revealed by molecular interaction studies. Nat Prod Rep 28(12):1937–1955. https://doi.org/10.1039/c1np00051a CrossRefPubMedPubMedCentral

Gupta SC, Patchva S, Koh W, Aggarwal BB (2012) Discovery of curcumin, a component of golden spice, and its miraculous biological activities. Clin Exp Pharmacol Physiol 39(3):283–299. https://doi.org/10.1111/j.1440-1681.2011.05648.x CrossRefPubMedPubMedCentral

Tang M, Taghibiglou C (2017) The mechanisms of action of curcumin in Alzheimer’s disease. J Alzheimers Dis 58(4):1003–1016. https://doi.org/10.3233/JAD-170188 CrossRefPubMed

Xie L, Li XK, Takahara S (2011) Curcumin has bright prospects for the treatment of multiple sclerosis. Int Immunopharmacol 11(3):323–330. https://doi.org/10.1016/j.intimp.2010.08.013 CrossRefPubMed

Miriyala S, Panchatcharam M, Rengarajulu P (2007) Cardioprotective effects of curcumin. Adv Exp Med Biol 595:359–377. https://doi.org/10.1007/978-0-387-46401-5_16 CrossRefPubMed

Sukardi R, Sastroasmoro S, Siregar NC, Djer MM, Suyatna FD, Sadikin M, Ibrahim N, Rahayuningsih SE, Witarto AB (2016) The role of curcumin as an inhibitor of oxidative stress caused by ischaemia re-perfusion injury in tetralogy of Fallot patients undergoing corrective surgery. Cardiol Young 26(3):431–438. https://doi.org/10.1017/S1047951115000360 CrossRefPubMed

10.

Panahi Y, Khalili N, Sahebi E, Namazi S, Karimian MS, Majeed M, Sahebkar A (2017) Antioxidant effects of curcuminoids in patients with type 2 diabetes mellitus: a randomized controlled trial. Inflammopharmacology 25(1):25–31. https://doi.org/10.1007/s10787-016-0301-4 CrossRefPubMed

11.

Chuengsamarn S, Rattanamongkolgul S, Luechapudiporn R, Phisalaphong C, Jirawatnotai S (2012) Curcumin extract for prevention of type 2 diabetes. Diabetes Care 35(11):2121–2127. https://doi.org/10.2337/dc12-0116 CrossRefPubMedPubMedCentral

12.

Abidi A, Gupta S, Agarwal M, Bhalla HL, Saluja M (2014) Evaluation of efficacy of curcumin as an add-on therapy in patients of bronchial asthma. J Clin Diagn Res 8(8):HC19–H24. https://doi.org/10.7860/JCDR/2014/9273.4705 CrossRefPubMedPubMedCentral

13.

Ye M, Zhang J, Zhang J, Miao Q, Yao L, Zhang J (2015) Curcumin promotes apoptosis by activating the p53-miR-192-5p/215-XIAP pathway in non-small cell lung cancer. Cancer Lett 357(1):196–205. https://doi.org/10.1016/j.canlet.2014.11.028 CrossRefPubMed

14.

Ammon HP, Wahl MA (1991) Pharmacology of curcuma longa. Planta Med 57(1):1–7. https://doi.org/10.1055/s-2006-960004 CrossRefPubMed

15.

Wahlstrom B, Blennow G (1978) A study on the fate of curcumin in the rat. Acta Pharmacol Toxicol (Copenh) 43(2):86–92CrossRef

16.

Pan MH, Huang TM, Lin JK (1999) Biotransformation of curcumin through reduction and glucuronidation in mice. Drug Metab Dispos 27(4):486–494PubMed

17.

Ireson C, Orr S, Jones DJ, Verschoyle R, Lim CK, Luo JL, Howells L, Plummer S, Jukes R, Williams M, Steward WP, Gescher A (2001) Characterization of metabolites of the chemopreventive agent curcumin in human and rat hepatocytes and in the rat in vivo, and evaluation of their ability to inhibit phorbol ester-induced prostaglandin E2 production. Cancer Res 61(3):1058–1064PubMed

18.

Sandur SK, Pandey MK, Sung B, Ahn KS, Murakami A, Sethi G, Limtrakul P, Badmaev V, Aggarwal BB (2007) Curcumin, demethoxycurcumin, bisdemethoxycurcumin, tetrahydrocurcumin and turmerones differentially regulate anti-inflammatory and anti-proliferative responses through a ROS-independent mechanism. Carcinogenesis 28(8):1765–1773. https://doi.org/10.1093/carcin/bgm123 CrossRefPubMed

19.

Vareed SK, Kakarala M, Ruffin MT, Crowell JA, Normolle DP, Djuric Z, Brenner DE (2008) Pharmacokinetics of curcumin conjugate metabolites in healthy human subjects. Cancer Epidemiol Biomark Prev 17 (6):1411–1417. https://doi.org/10.1158/1055-9965.EPI-07-2693 CrossRef

20.

Shoba G, Joy D, Joseph T, Majeed M, Rajendran R, Srinivas PS (1998) Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers. Planta Med 64(4):353–356. https://doi.org/10.1055/s-2006-957450 CrossRefPubMed

21.

Purpura M, Lowery RP, Wilson JM, Mannan H, Munch G, Razmovski-Naumovski V (2017) Analysis of different innovative formulations of curcumin for improved relative oral bioavailability in human subjects. Eur J Nutr. https://doi.org/10.1007/s00394-016-1376-9 CrossRefPubMedPubMedCentral

22.

Nazari-Vanani R, Moezi L, Heli H (2017) In vivo evaluation of a self-nanoemulsifying drug delivery system for curcumin. Biomed Pharmacother 88:715–720. https://doi.org/10.1016/j.biopha.2017.01.102 CrossRefPubMed

23.

Cuomo J, Appendino G, Dern AS, Schneider E, McKinnon TP, Brown MJ, Togni S, Dixon BM (2011) Comparative absorption of a standardized curcuminoid mixture and its lecithin formulation. J Nat Prod 74(4):664–669. https://doi.org/10.1021/np1007262 CrossRefPubMed

24.

Jager R, Lowery RP, Calvanese AV, Joy JM, Purpura M, Wilson JM (2014) Comparative absorption of curcumin formulations. Nutr J 13:11. https://doi.org/10.1186/1475-2891-13-11 CrossRefPubMedPubMedCentral

25.

Hussain Z, Thu HE, Amjad MW, Hussain F, Ahmed TA, Khan S (2017) Exploring recent developments to improve antioxidant, anti-inflammatory and antimicrobial efficacy of curcumin: A review of new trends and future perspectives. Mater Sci Eng C Mater Biol Appl 77:1316–1326. https://doi.org/10.1016/j.msec.2017.03.226 CrossRefPubMed

26.

Sasaki H, Sunagawa Y, Takahashi K, Imaizumi A, Fukuda H, Hashimoto T, Wada H, Katanasaka Y, Kakeya H, Fujita M, Hasegawa K, Morimoto T (2011) Innovative preparation of curcumin for improved oral bioavailability. Biol Pharm Bull 34(5):660–665CrossRefPubMed

27.

Rahimi HR, Nedaeinia R, Sepehri Shamloo A, Nikdoust S, Kazemi Oskuee R (2016) Novel delivery system for natural products: nano-curcumin formulations. Avicenna J Phytomed 6(4):383–398PubMedPubMedCentral

28.

Antony B, Merina B, Iyer VS, Judy N, Lennertz K, Joyal S (2008) A pilot cross-over study to evaluate human oral bioavailability of BCM-95CG (Biocurcumax), a novel bioenhanced preparation of curcumin. Indian J Pharm Sci 70(4):445–449. https://doi.org/10.4103/0250-474X.44591 CrossRefPubMedPubMedCentral

29.

Artursson P, Karlsson J (1991) Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells. Biochem Biophys Res Commun 175(3):880–885CrossRefPubMed

30.

Adiwidjaja J, McLachlan AJ, Boddy AV (2017) Curcumin as a clinically-promising anti-cancer agent: pharmacokinetics and drug interactions. Expert Opin Drug Metab Toxicol. https://doi.org/10.1080/17425255.2017.1360279 CrossRefPubMed

31.

Akazawa N, Choi Y, Miyaki A, Tanabe Y, Sugawara J, Ajisaka R, Maeda S (2012) Curcumin ingestion and exercise training improve vascular endothelial function in postmenopausal women. Nutr Res 32(10):795–799. https://doi.org/10.1016/j.nutres.2012.09.002 CrossRefPubMed

32.

Schiborr C, Kocher A, Behnam D, Jandasek J, Toelstede S, Frank J (2014) The oral bioavailability of curcumin from micronized powder and liquid micelles is significantly increased in healthy humans and differs between sexes. Mol Nutr Food Res 58(3):516–527. https://doi.org/10.1002/mnfr.201300724 CrossRefPubMed

33.

Meibohm B, Beierle I, Derendorf H (2002) How important are gender differences in pharmacokinetics? Clin Pharmacokinet 41(5):329–342. https://doi.org/10.2165/00003088-200241050-00002 CrossRefPubMed

Title: Increased bioavailability of curcumin using a novel dispersion technology system (LipiSperse®)
Authors: D. Briskey
A. Sax
A. R. Mallard
A. Rao
Publication date: 01-08-2019
Publisher: Springer Berlin Heidelberg
Published in: European Journal of Nutrition / Issue 5/2019
Print ISSN: 1436-6207
Electronic ISSN: 1436-6215
DOI: https://doi.org/10.1007/s00394-018-1766-2

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

Illustration of figure on mountain summit/© Orapun / Stock.adobe.com, STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 5/2019

Pharmacokinetics of vitamin E, γ-oryzanol, and ferulic acid in healthy humans after the ingestion of a rice bran-enriched porridge prepared with water or with milk

Eating patterns of Australian adults: associations with blood pressure and hypertension prevalence

Diet as moderator in the association of adiposity with inflammatory biomarkers among adolescents in the HELENA study

Selenium and sulphur derivatives of hydroxytyrosol: inhibition of lipid peroxidation in liver microsomes of vitamin E-deficient rats

Iron bioavailability of four iron sources used to fortify infant cereals, using anemic weaning pigs as a model

An open-label, randomized, placebo-controlled study on the effectiveness of a novel probiotics administration protocol (ProbiotiCKD) in patients with mild renal insufficiency (stage 3a of CKD)

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage